Excipients in Pharmaceuticals: Global Markets to 2022
24 April 2018
The global market for pharmaceutical excipients will grow from nearly $6.8 billion in 2017 to $8.7 billion by 2022 with a compound annual growth rate (CAGR) of 4.9% for the period of 2017-2022.
- 58 tables
- An overview of the global market for excipients in pharmaceuticals
- Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Detailed analyses of organic and inorganic excipients
- Discussion of various excipient interactions, including drug-excipient interaction, excipient-excipient interaction, and package-excipient interaction
- Insight into the most critical issues surrounding excipients, including technological, regulatory, economic, and political
- Company profiles of major players in the market, including Ashland Global Holdings, Inc., Cargill, Inc, Meggle Pharma Gmbh, The Lubrizol Corporation and Omya Ag
This report on the pharmaceutical excipient market covers an overview of excipients, classification of excipients, and their significance in the pharmaceutical industry. A detailed analysis illustrating market dynamics, market structure analysis incorporating Porter’s Five Force Framework analysis and supply chain and distribution is discussed in detail. Excluded from the scope of this report is the use of excipients in cosmetics, food and beverage, and chemical industries. Emerging pharmaceutical excipients such as co-processed and multifunctional excipients and their impact on the future of pharmaceutical excipients market is also analyzed.
Based on the type of material, the pharmaceutical excipient market is segmented into organic excipients, inorganic excipients and USP Water. Based on route of administration, the pharmaceutical excipient market is segmented by-oral, injectable/parenteral, topical and advanced delivery systems. By dosage forms, the pharmaceutical excipients market is segmented as solid dosage forms, liquid dosage forms, semi-solid dosage forms, and others (e.g., aerosol and powder). By end user, the market is segmented into pharmaceutical and biopharmaceutical companies, contract formulators and others (e.g., academics and pharmacies). This report includes market size estimates for 2016 as the base year, 2017, and forecast estimates for 2022.
Geographically, this report analyzes the market by the following regions: North America, Europe, Asia-Pacific, Latin America and the Middle East. Key countries with a high concentration of pharma manufacturing companies and contract manufacturing organizations, including the U.S., Europe (Germany, U.K., Italy, France and Spain), China, India and Brazil are discussed. A detailed competitive analysis of key leading pharmaceutical excipient suppliers is provided, detailing business operations and segment focus.
Led by Research Head Karthik Arun, the BCC Research staff is composed of expert analysts skilled in conducting primary research, secondary research and data analysis and who have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in microbiology, electrical engineering, business administration, surgery and other subject areas.
The global excipients market should reach nearly $6.9 billion by 2020 from approximately $6.3 billion in 2015, at a compound annual growth rate (CAGR) of 1.9% from 2015 to 2020.
- An overview of the global market for excipients in pharmaceuticals, including examinations of the effects of a crisis in the global supply chain, the demands of quality by design (QbD), and concerns about drug safety.
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020.
- Discussion of positive trends in the industry, including the development of creative ideas in response to the need for new excipients and new levels of cooperation between major players.
- Coverage of the most important issues surrounding excipients: technological, regulatory, economic, and political.
- Evaluations of excipient technology by chemical compounds, functional uses, delivery systems and finished products.
- Profiles of suppliers and others relevant to the industry.
The global excipient market reached nearly $5.9 billion in 2012. This market is expected to grow to $6.3 billion in 2013 and then to $8.8 billion in 2018, a compound annual growth rate (CAGR) of 6.9% over the five-year period from 2013 to 2018.
- An overview of the global market for excipients in pharmaceuticals, including examinations of the effects of a crisis in the global supply chain, the demands of quality by design (QbD), and concerns about drug safety
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
- Discussion of positive trends in the industry, including the development of creative ideas in response to the need for new excipients and new levels of cooperation between major players
- Coverage of the most important issues surrounding excipients: technological, regulatory, economic, and political
- Evaluations of excipient technology by chemical compounds, functional uses, delivery systems and finished products
- Comprehensive company profiles of suppliers and others relevant to the industry.
The global excipients market was at $4.6 billion in 2010 and it is expected to reach at $4.9 billion in 2011. It is further anticipated to increase to $6.7 billion by 2016 at a compound annual growth rate (CAGR) of 6.5%.
- Overall sales in the global excipients market were worth $4.1 billion in 2008, and increased to an estimated $4.3 billion in 2009. By 2014, it is projected to increase to $5.9 billion, for a 5-year compound annual growth rate (CAGR) of 6.3%.
- The largest segment of the market, organic chemicals, was valued at $3.8 billion in 2008; this is expected to increase to $4 billion in 2009, and is projected to reach $5.5 billion in 2014, for a 5-year CAGR of 6.4%.
- Sales in the USP (U.S. Pharmacopeia-grade) Water segment amounted to $79 million in 2008, increased to an estimated $84 million in 2009, and is projected to increase to $104 million in 2014, for a 5-year CAGR of 4.4%.
The chemical compounds used to make excipients are valued at $4.3 billion market value for 2011, up from $3.5 billion in 2006. The dominance of USP water, particularly water for injection, skews the market volume and sets the pace for the anticipated 5.1% average annual market volume growth rate over the next five years.
Formulators will continue to use excipients to give their final drug products the necessary or desired functional use or properties. Vehicles, with an estimated 2011 market volume of 9.6 billion pounds, lead due to the large amount of USP water consumed.
Fillers follow with an estimated 849 million pounds of excipient chemical compounds being used in that functional category in five years. In terms of market value, the situation is reversed. Fillers come out on top, with an estimated 2011 market value of $1.2 billion, and vehicles drop to third place with $781 million, just below emollients at $816 million.
In 2001, the global market for pharmaceutical (drug) inert ingredients was an estimated 7.25 billion pounds, of which water, accounted for about 77% of the total.
Overall growth of all drug inert ingredients is the order of 5% per year.
Injectables, essentially all Rx, constitute the single largest dosage form of excipients used in 2001 with almost 1.9 billion Kgs.
Nonaqueous biological use will grow to 563 million Kgs by 2007, an average annual growth rate (AAGR) of 4.5%.